Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.

International journal of cancer - 15 Nov 2026

Wang Jinxia, Qi Ping, Li Jinhua, Wang Na, Fu Caihong, Liu Lixin, Li Shuping, Li Xiao, Hou Xiaoming, Qiao Hui

Abstract excerpt

While third-generation EGFR tyrosine kinase inhibitors (TKIs) improve outcomes in EGFR-mutant NSCLC, optimal selection between these agents remains uncertain. This real-world study compares the efficacy and safety of aumolertinib with those of osimertinib in the first-line treatment setting. We retrospectively analyzed 109 EGFR-mutant (exon 19del/L858R) NSCLC patients treated with first-line aumolertinib (n = 53)...

Read the complete abstract on PubMed

Topics

Acrylamides
Humans
Aniline Compounds
Pyrimidines
Carcinoma, Non-Small-Cell Lung
Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Retrospective Studies

Lung Neoplasms

ErbB Receptors

Mutation

Female

Male

Aged

Middle Aged

Protein Kinase Inhibitors

Progression-Free Survival

Aged, 80 and over

Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 42552814
DOI: 10.1002/ijc.70617
PMCID: PMC13595493

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.PMID 42552814Read ↗

A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study.Semantic proximity Read ↗

Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIsSemantic proximity Read ↗

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.Semantic proximity Read ↗

Outcomes of first-line osimertinib treatment for epidermal growth factor receptor-mutated non-small cell lung cancer in clinical practice settingsSemantic proximity Read ↗

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.Semantic proximity Read ↗

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.Semantic proximity Read ↗

Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.Semantic proximity Read ↗

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)Semantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.Semantic proximity Read ↗

The Real-Life Efficacy And Safety of Osimertinib In Pretreated Advanced Non-Small Cell Lung Cancer Patients With T790M Mutation: A Turkish Oncology Group StudySemantic proximity Read ↗

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.